A Phase III, Multicentre, Open Label, Comparative, Dose-interval Titration Study Evaluating the Efficacy and Safety of Six Repeated Deep Subcutaneous Administrations of Lanreotide Autogel 120mg, in Acromegalic Patients Previously Treated With Octreotide LAR
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Sponsors Ipsen
Most Recent Events
- 16 Jan 2019 New trial record